KR20080029989A - Lipase inhibitor including processed ginseng, functional food and medical composition including the lipase inhibitor - Google Patents

Abstract

A lipase inhibitor including a processed ginseng product is provided. Functional food including the lipase inhibitor has effects such as anti-obesity, anti-hyperlipidemia, anti-hypercholesterolemia, anti-hypertriglyceridemia and glycemic control. Functional food contains a lipase inhibitor including a processed ginseng product which is obtained by fermentation of ginseng with lactic acid bacteria. The ginseng is selected from the group consisting of raw ginseng, red ginseng, white ginseng, the root hair of ginseng, Panax quinquefolia, ginseng leaf and ginseng powder. The lactic acid bacteria is selected from the group consisting of strains of lactic acid bacteria belonging to the genus Lactobacillus, Streptococcus, Leuconostoc, Pediococcus, Bifidobacterium and its combination.

Description

Lipase inhibitors containing processed ginseng products, functional foods and pharmaceutical compositions comprising same {LIPASE INHIBITOR INCLUDING PROCESSED GINSENG, FUNCTIONAL FOOD AND MEDICAL COMPOSITION INCLUDING THE LIPASE INHIBITOR}

The present invention relates to a lipase inhibitor comprising a ginseng extract or a ginseng fermentation product and a functional food and pharmaceutical composition comprising the lipase inhibitor, and more particularly, a ginseng fermentation product treated with a ginseng extract or lactic acid bacteria, and inhibiting obesity. It relates to a lipase inhibitor having the efficacy of anti-hyperlipidemia, anti-blood hypercholesterol, anti-blood triglycerides, blood sugar control and the like, and a functional food and pharmaceutical composition comprising the lipase inhibitor.

Triglyceride in food is hydrolyzed into fatty acids and monoglycerides by the action of pancreatic lipase, and the fatty acids produced by the hydrolysis form micelles with cholesterol. Accordingly, fatty acids are absorbed into the body in the form of the micelles. Lipase is a kind of esterase, which breaks down the ingested lipids into fatty acids and glycerol. There are gastric lipases and pancreatic lipases in the human body, but fat digestion is rarely caused by gastric lipases, and is mostly done in the intestine by pancreatic lipases [Goldstein JL, Schrott H., Hazzard E., Bierman E., Motuski A., J. Clin. Invest., 52 , 1544-1568 (1973); Rodwell VW, McNamara DJ, Shapiro DJ, Adv. Enzymol., 38 , 373-412 (1973); Carey MC, Small DM, Bliss CM, Annu. Rev. Physiol., 45 , 651-677 (1983)].

Lipase inhibitors are intestinal lipase inhibitors. When lipases are inactivated, they cannot be hydrolyzed into monoglycerides and free fatty acids that can absorb dietary fat, and neutral fats that do not degrade are not absorbed into the body. Has the effect of inducing calorie reduction. Therefore, it can be used for the treatment of obesity and can be used for weight loss and maintenance with low calorie diet. In particular, the inhibition of the lipolytic enzyme is important for the absorption of fat components such as triglycerides and cholesterol in the blood. In particular, the increase in fat in the blood is known to be a cause of circulatory diseases, so lowering the fat component in the blood can be applied to the prevention and treatment of circulatory diseases. Hyperlipidemia, which is caused by an increase in fat content in the blood, is caused by excessive intake of cholesterol and triglycerides and increased biosynthesis or degradation of lipoproteins in the presence of elevated lipid concentrations in the plasma. It is also caused by abnormalities in lipoprotein metabolism, such as delayed lipoprotein removal rate in plasma. In particular, hypercholesterolemia causes ischemic heart disease and atherosclerosis [Lee Kwang Woo, Diabetes and Obesity. Diabetes mellitus, 14 (1) 5-11 (1990); Lee Hong-kyu, a disease associated with obesity. Korean Journal of Obesity, 1 (1), 34-39 (1992); Min-Young Jung, a companion disease of obesity. Korean Journal of Obesity, 1 (1), 5-10 (1992); Clinical Obesity, College of Obesity. Korea Medicine. 281-283 (1995). Therefore, research on the development of lipase inhibitors is medically and nutritionally important, and many researchers have focused on developing lipase inhibitors derived from natural products [N. B. Cater and S. M. Grundy, International Journal of Obesity., 3 (35), 11 (1987)].

On the other hand, diabetes is a type of chronic disease that occurs a lot in modern people. In Korea, the number of diabetics has increased rapidly since the 1980s, and the number reaches 10% of the population. In general, diabetes mellitus is treated as a kind of culture disease that occurs intensively at the age of 40 to 50 years of age, but there is a trend that pediatric diabetics are also increasing according to changes in diet.

Diabetes can be divided into type I and type II, which are genetically developed depending on the cause, due to a decline in interest function due to virus infection and the like. Type I is also called insulin-dependent diabetes because it requires insulin for its treatment, and these type I diabetes patients account for about 10% of all diabetics. Type II diabetes is more common in people over 40 years of age, accounting for about 90% of all diabetics, also called insulin-independent diabetes. Type II diabetes is mainly caused by obesity, overwork, stress, the onset of surgery or other diseases, pregnancy and the like. On the other hand, specific complications of diabetes include diabetic neuropathy and retinopathy.

Currently, α-glycosidase (alpha amylase, maltase, etc.) that acts on insulin, or to inhibit insulin production promoting substances, or starch, to control the concentration of glucose (glucose) in the blood of diabetic patients as described above. Inhibitors, glucose absorption inhibitors, and the like have been developed.

On the other hand, ginseng is a perennial ripening root belonging to the genus Oga ginseng according to the plant taxonomy, and about 11 species are known on the earth.For example, the ginseng grows in the Far East of Asia (33-48 degrees North: Korea, North Manchuria, and Russia). Korean ginseng (Panax ginseng CAMeyer) with very good efficacy; American ginseng (Panax quinquefolium L .; aka Hwagi) grown and grown in the United States and Canada; Panax notoginseng F.H.Chen, wild or cultivated in southwestern Guangxi province from southeastern Yunnan Province of China; And Panax japonicus C.A.Meyer distributed to Japan, southwest China, and Nepal.

Ginseng has been used as a commodity in the new agricultural herb and has been used as a valuable medicine since ancient times. Through many pharmacological experiments, ginseng not only enhances the non-specific resistance of the body to stress, but also acts as an antioxidant. It has been found to have improved hypertension, enhanced insulin action, hypoglycemic effect in alloxic diabetic mice, liver RNA synthesis in rats, protein synthesis, sugar and lipid metabolism promoting effects, and anticancer effects.

Ginseng has been used in the treatment of various diseases such as psychiatric diseases, nervous system diseases, diabetes mellitus in the form of herbal medicine mainly in Asian countries such as Korea, China, Japan, etc. Saponin, the main component of the ginseng, is tonic, gangjeong, soothing It is known to have an effect on molding and antihypertension.

Currently, ginseng is white ginseng, which has been grown and harvested as it is, at room temperature, red ginseng prepared by heat treatment at a temperature of 98 to 100 ° C., or high temperature treatment prepared by heat treatment at a temperature of 120 to 180 ° C. It is used in the form of ginseng (eg ginseng, black ginseng).

The root of the ginseng contains about 4 to 10% of ginseng saponin (Korean ginseng contains 4 to 8%, American ginseng contains 4 to 10% saponins), and such ginseng saponins are various ginsenosides (ginsenosides). Mixture of these. Among them, Korean ginseng contains a relatively high content of ginsenosides Rb1, Rc and Rg1, US ginseng contains a relatively high content of ginsenosides Rb1 and Re. Until now, the effects of ginseng on the anti-cancer, central nervous system, anti-allergic effect, immune enhancing effect, anti-diabetic, blood lipid-lowering effect, etc. are widely known, but the blood lipid-lowering effect and anti-diabetic effect of ginseng fermentation It has not been studied or reported at all.

The present inventors have studied the lipase inhibitory effect of the ginseng extract or ginseng fermentation, and completed the present invention by discovering that the ginseng processed product including the effective amount of the substance exerts an excellent effect on the inhibition of obesity.

Accordingly, it is an object of the present invention to provide a novel lipase inhibitor comprising a ginseng processed product containing a ginseng extract or a ginseng fermentation product that can effectively inhibit lipase.

Another object of the present invention is to provide a functional food comprising the processed ginseng product and having an effect of inhibiting obesity, anti-hyperlipidemia, anti-blood high cholesterol, anti-blood triglyceride, blood sugar control, and the like.

Still another object of the present invention is to provide a pharmaceutical composition comprising the ginseng fermented product and having an effect of inhibiting obesity, anti-hyperlipidemia, anti-blood cholesterol, anti-blood triglycerides, glycemic control, and the like.

In order to achieve the above object, the present invention provides a lipase inhibitor comprising a ginseng processed product containing ginseng extract, ginseng fermented product or a combination thereof.

According to one embodiment of the present invention, the ginseng may include ginseng, red ginseng, white ginseng, rice ginseng, hwagi ginseng, ginseng leaves, ginseng extract, ginseng powder, and the like, and also ginseng and red ginseng in a dry powder form, hot ginseng And pressurized ginseng.

On the other hand, the ginseng fermentation may be obtained by fermenting ginseng into lactic acid bacteria.

In the present invention, lactic acid bacteria that can be used include strains of the genus Lactobacillus, strains of Streptococcus, strains of Leukonostock, strains of Pediococcus, strains of Bifidobacterium, and more specifically, BP Bifidobacterium K-103, Bifidobacterium K-506, Bifidobacterium cholerium KK-1 (KCCM-10364), Bifidobacterium minimum KK-2 (KCCM-10365), Bifidobacterium H -1 (KCCM-10493), Lactobacillus ashidophilus K-1, Lactobacillus ashidophilus K-2, Streptococcus fascium K-2, Leukonostock mesentoid K-1, Leukonostock messen Theroid K-2, Saccharomyces cerevisiae K-1, Ganoderma lucidum K-1, etc. are mentioned.

In order to achieve the other object of the present invention, the present invention includes a lipase inhibitor containing a processed ginseng, and functional to exert the effect of inhibiting obesity, anti-hyperlipidemia, anti-blood high cholesterol, anti-blood triglyceride, blood sugar control, etc. Provide food.

In order to achieve another object of the present invention, the present invention includes a lipase inhibitor comprising a ginseng processed product, and exhibits the efficacy of inhibiting obesity, anti-hyperlipidemia, anti-hypercholesterol, anti-blood triglycerides, glycemic control, etc. Provide a pharmaceutical composition.

According to the present invention, the lipase inhibitor including ginseng extract or ginseng fermentation inhibits the activity of lipolytic enzymes, thereby effectively inhibiting obesity, blood hyperlipidemia, blood high cholesterol, and blood triglycerides, and effectively controlling blood sugar. have.

As described above with reference to the preferred embodiment of the present invention, those skilled in the art can variously modify and change the present invention without departing from the spirit and scope of the present invention described in the claims below. I can understand that.

Through the present specification, "ginseng" means not only Korean ginseng (Panax ginseng CAMeyer) that grows in Korea, but also Hwagisam (Panax quinquefolium L.), Panax notoginseng FHChen, and Panax ginseng (Panax japonicus). CAMeyer)) and the like can be included.

Hereinafter, the present invention will be described in more detail.

Lipase inhibitors of the present invention include ginseng extract or ginseng fermentation.

The ginseng extract or the ginseng fermented product included in the lipase inhibitor may prevent the ingested fat from being hydrolyzed into an absorbable form by inhibiting the activity of the lipase, that is, lipase. The ginseng extract or ginseng fermented product may be subjected to any form of physical and chemical processing as long as it exerts a function of inhibiting the activity of lipolytic enzymes.

Ginseng fermentation product according to the present invention can be obtained by fermenting ginseng into lactic acid bacteria.

In the present invention, the method for obtaining the ginseng fermentation can be used as long as it is a conventional method in the art, there is no particular limitation. For example, ginseng fermentation can be obtained by fermenting ginseng using lactic acid bacteria under suitable fermentation conditions. Specifically, after suspending the ginseng raw material in water and adding lactic acid bacteria to this, and after the bioconversion process to obtain the lactic acid bacteria fermentation product of the ginseng by culturing the lactic acid bacteria in about 48 hours to about 72 hours at an appropriate fermentation temperature, It can be obtained by centrifuging the crude lactic acid bacteria fermentation product of ginseng obtained in the above process and filtering only the supernatant to concentrate the crude lactic acid bacteria fermentation product.

The ginseng raw material for obtaining the ginseng fermentation product according to the present invention includes not only ginseng itself but also ginseng that has been subjected to a specific processing, specifically, ginseng, red ginseng, white ginseng, rice ginseng, flower ginseng, ginseng leaf, ginseng extract, ginseng powder Etc. can be mentioned. They may be used alone or in combination, as well as ginseng or red ginseng in dry powder form, hot ginseng, pressurized ginseng. The ginseng in dry powder form may be prepared by a method commonly used in the art, and there is no particular limitation on the degree of powdering, and the ginseng is sufficient to effectively penetrate into ginseng tissue or fiber. On the other hand, high-temperature ginseng and pressurized ginseng may be prepared from ginseng itself, but it is preferable in effect and subsequent fermentation efficiency to obtain from ginseng in the form of dry powder described above. Even in this case, there is no particular limitation on the powdering degree of ginseng in dry powder form.

As lactic acid bacteria that can be used in the production of the ginseng fermentation product according to the present invention, strains of the genus Lactobacillus, strains of Streptococcus, strains of the genus Leukonostok, strains of Pediococcus, strains of Bifidobacterium, etc. Among them, strains having a high production rate of compound K, ginsenoside Rh1 and Rh2, Rh3, Rk2 of saponin components in ginseng are more preferable. These can be used individually or in mixture.

As a specific example of usable lactic acid bacteria, Bifidobacterium K-103 isolated from Korean intestinal bacterial flora (see Kyung Hee University Pharmacy Lab, Arch . Pharm . Res . , 21, 54-61, 1998), BPI Terium K-506 (see Kyung Hee University Pharmacy Lab, Arch . Pharm. Res . , 21, 54-61, 1998), Bifidobacterium cholerium KK-1 (KCCM-10364), Bifidobacterium minimum KK -2 (KCCM-10365), Bifidobacterium H-1 (KCCM-10493), Lactobacillus acidophilus K-1 (Professor, Dong-Hyun Kim, Kyung Hee University), Lactobacillus acidophilus K-2 (Professor, Dong-Hyun Kim, Kyung Hee University), Streptococcus faecium K -2 (Dept. Of Pharmacy Kim, Kyung Hee University), Streptococcus faecium K-2 (Dept. of Pharmacy, Kyung Hee University), Leuconostoc mesenteroides K-1 (Kim, Hee University, Kyung Hee University), Leuconostoci mesenteroides K-2 Classroom), Saccharomyces ce isolated from yeast reveiseiae K-1 (Professor Dong-Hyun Kim, Kyung Hee University) and Gonoderma lucidum K-1 (Professor Kim Dong-Hyun, Kyung Hee University). These can be used individually or in mixture.

In addition to the lactic acid bacteria described above, among the various lactic acid bacteria commonly used in the art, all of the lactic acid bacteria which can prepare a ginseng fermentation product having excellent hypoglycemic effect, hypolipidemic effect, etc. can be used in the present invention, and are limited to the above-described range. It doesn't happen.

As such, when the ginseng is fermented with lactic acid bacteria, the compound K component (20- O- β-D-glucopyranosyl-20 ( S ) -protopanaxadiol), which is an active saponin, ginsenosides Rh1 and Rh2, Rh3 (△ ²⁰ -jin) Cenosides Rh2), Rk2 (△ ²⁰ -ginsenosides Rh2) and the like will be increased in content, according to the ginseng fermentation can exhibit excellent blood sugar lowering effect, blood lipid lowering effect.

Lipase inhibitors according to the invention may further comprise suitable excipients according to conventional methods. Examples of excipients that may be included in the compositions of the present invention include gum, lactose, mung beans, vitamin C, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, mineral oil and the like, but are not limited thereto. As long as it is conventionally used in the art to which the present invention pertains and does not show adverse effects on lipase inhibition, any one can be used.

Functional foods according to the present invention by including a lipase inhibitor containing a ginseng extract or ginseng fermented products, it can exert an effect such as obesity inhibition, anti-hyperlipidemia, anti-blood high cholesterol, anti-blood triglycerides, glycemic control. In the present invention, the food is a general concept including foodstuffs, food additives, food ingredients, etc., as well as those directly ingestible. The functional food according to the present invention may be used by directly adding the lipase inhibitor alone, but may exhibit synergism by adding a known or new substance used for the prevention and treatment of obesity, anti-hyperlipidemia, blood sugar control, etc. have. In addition, general additives such as food coloring, food flavoring, herbal medicine, fruit, oligosaccharide, chitosan, citric acid, etc. may be used to give a good taste and aroma.

Functional foods containing lipase inhibitors of the present invention include confectionery such as bread, rice cakes, dried fruits, candy, chocolates, chewing gum, and nuts; Ice cream products such as ice creams, ice creams, and ice cream powders; Dairy products such as milks, low fat milks, lactose digested milk, processed milk, goat milk, fermented milk, butter milk, concentrated milk, milk cream, butter oil, natural cheese, processed cheese, milk powder, whey; Meat products such as meat products, processed products, and hamburgers; Fish meat products such as fish meat products such as fish paste, ham, sausage and bacon; Noodles such as ramen noodles, dried noodles, raw noodles, fried noodles, dehydrated noodles, refined noodles, frozen noodles and pasta; Beverages such as fruit beverages, vegetable beverages, carbonated beverages, lactic acid bacteria beverages such as soy milk and yogurt, mixed beverages; Seasoning foods such as soy sauce, miso, red pepper paste, chunjang, cheongukjang, mixed soy sauce, vinegar, sauce, tomato ketchup, curry, and dressing; Margarine, shortening; And pizza, but are not limited thereto.

The pharmaceutical composition according to the present invention includes a lipase inhibitor containing a ginseng extract or a ginseng fermented product, thereby preventing and treating obesity, anti-hyperlipidemia, anti-blood cholesterol, anti-blood triglycerides, and the like, and blood sugar Very effective in regulation. A pharmaceutical acceptable carrier may be added to the pharmaceutical composition according to the present invention according to a pharmaceutical preparation method known in the art.

Examples of carriers usable in the present invention include lactose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like, but are not limited thereto.

In addition, the lipase inhibitor may further include fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers or preservatives.

The pharmaceutical compositions according to the present invention may be used in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods. Can be.

The pharmaceutical composition containing the lipase inhibitor of the present invention can be used clinically for the prevention and treatment of obesity, control of triglycerides in blood, lowering cholesterol levels, improving blood pressure, treating hyperlipidemia and diabetes.

Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples. However, it is to be understood that the following examples are intended to illustrate the invention and are not intended to limit the invention.

< Ginseng Extract and Ginseng Fermented product  Manufacture

Example  One

At temperatures of 40 ° C. (temperature ranges from room temperature to 100 ° C. are sufficient, suitably between 40 ° C. and 80 ° C.), using 70% alcohol (water or alcohol may be used), ginseng ( The extract was obtained by extracting 5 years old Korean ginseng from Geumsan purchased from Gyeongdong Market, or concentrated under reduced pressure to obtain X.

Example  2

At a temperature of 40 ° C. (a temperature range of 4 ° C. to 60 ° C. is sufficient, and suitably a temperature of 50 ° C. to 80 ° C.), red ginseng (using water or alcohol may be used), using 70% alcohol 5 years old ginseng prepared with Korean ginseng) was extracted or concentrated under reduced pressure to obtain X.

Example  3

Steamed ginseng steamed at a temperature of 120 ° C. under reduced pressure and dried at 65 ° C. was heated at a temperature of 40 ° C. (a temperature range of room temperature to 100 ° C. is sufficient, and a temperature of 40 ° C. to 80 ° C.), 70 Extraction was obtained by extraction with% alcohol (water or alcohol may be used), or it was concentrated under reduced pressure to obtain X.

Example  4

1 g (0.1 to 10 g) of fresh ginseng powder obtained by washing ginseng (5 years of Korean ginseng from Kumsan acid purchased from Gyeongdong Market) with dry water, and then powdering it finely, preferably 1 to 10 g 2 g) was suspended in 100 ml of distilled water. Subsequently, 1 ml (about 10 ⁹ cells / ml) of each of the lactic acid bacteria Bifidobacterium long gum H-1 strains previously cultured were transplanted, and the cells were incubated at 37 ° C. for 24 hours and then lyophilized.

Example  5

Red ginseng (obtained from ginseng (5 years old Korean ginseng) at 98 ℃ temperature for 2 hours, then dried for 4 hours at 65 ℃) well washed with hot water and dried, and then finely powdered 1 g of red ginseng powder (0.1-10 g is sufficient, suitably 1-2 g) was suspended in 100 ml of distilled water. Subsequently, 1 ml (about 10 ⁹ cells / ml) of each of the lactic acid bacteria Bifidobacterium long gum strains previously cultured were transplanted, which were incubated at 37 ° C. for 12 hours, and then lyophilized.

Example  6

Red ginseng (obtained from Korean ginseng (5 years old Korean ginseng) at a temperature of 98 ℃ for 2 hours, dried for 4 hours at 65 ℃) well washed with hot water and dried, and then finely powdered 1 g of red ginseng powder (0.1 to 10 g is sufficient, suitably 1 to 2 g) was suspended in 100 ml of water. Subsequently, 1 ml (about 10 ⁹ cells / ml) of each of the Lactobacillus acidophilus K-1 strains were transplanted, which were incubated at 37 ° C. for 12 hours, and then lyophilized.

Example  7

Red ginseng (obtained from Korean ginseng (5 years old Korean ginseng) at a temperature of 98 ℃ for 2 hours, dried for 4 hours at 65 ℃) well washed with hot water and dried, and then finely powdered 1 g of red ginseng powder (0.1 to 10 g is sufficient, suitably 1 to 2 g) was suspended in 100 ml of water. Subsequently, 1 ml (about 10 ⁹ cells / ml) of each Streptococcus faecium K-1 strain was transplanted, which was incubated at 37 ° C. for 12 hours, and then lyophilized.

Example  8

Red ginseng (obtained from Korean ginseng (5 years old Korean ginseng) at a temperature of 98 ℃ for 2 hours, dried for 4 hours at 65 ℃) well washed with hot water and dried, and then finely powdered 1 g of red ginseng powder (0.1 to 10 g is sufficient, suitably 1 to 2 g) was added to 100 ml of water and suspended. Subsequently, 1 ml (about 10 ⁹ cells / ml) of each of the strains of Leuconostoc mesenteroides K-1 was transplanted and incubated at 37 ° C. for 12 hours, and then lyophilized.

Example  9

Under reduced pressure, steamed at 120 ° C, 2 g of hot-treated ginseng powder and 0.1 g of vitamin C dried at 65 ° C were suspended in 100 ml of milk, and then pre-cultivated Lactobacillus Bifidobacterium long gum H-1 strain was incubated, respectively. 1 ml (approximately 10 ⁹ cells / ml) were implanted, which were incubated at a temperature of 37 ° C. for 24 hours and then lyophilized.

< Experimental Example  1: Content Analysis of Saponin Content>

2 g each of the ginseng processed products prepared in Examples 1 to 9 were taken, extracted three times with 100 ml of methanol, and the concentrate was suspended in water. Then it was extracted three times with 100 ml of ether, and again three times with 100 ml of butanol, and the concentrate obtained by concentrating the butanol fraction was dissolved in methanol again and subjected to TLC analysis (CHCl ₃ : MeOH: An underlayer solution of H ₂ O = 65:35:10; a 5% sulfuric acid solution in MeOH as a color reagent; model CS-9301PC as a detector, Shimadzu Corporation, Japan). The saponin content of the ginseng processed product thus measured is shown in Table 1 below.

Saponin Content in Saponin Extract Fraction of Ginseng Extract and Ginseng Fermentation (%) Rb1 Rg1  Rg3 CK Rh1 Rh2 Rf1  PPD  PPT Example 1 14.2 12.2 <1 <1 <1 <1 <1 <1 <1 Example 2 7.5 10.2 6.2 <1 <1 <1 <1 <1 <1 Example 3 4.9 8.7 10.3 <1 1.2 <1 <1 <1 <1 Example 4 7.8 7.5 <1 4.2 2.2 <1 <1 <1 1.1 Example 5 3.9 8.4 8.9 <1 1.5 1.0 1.1 <1 1.2 Example 6 6.4 10.2 7.1 <1 <1 <1 <1 <1 <1 Example 7 6.8 9.1 5.2 <1 <1 <1 <1 <1 <1 Example 8 5.5 9.2 6.8 <1 <1 <1 One <1 <1 Example 9 2.2 3.8 5.2 1.5 2.1 3.5 1.5 1.1 1.3

< Experimental Example  2: In vitro pancreatic lipase inhibitory activity test>

Acacia rubber was dissolved in distilled water to 10%, triolein was added to 206 mM and mixed for 5 minutes. After homogenization by the above mixture, 40 μl of glycocholate solution with 20 mM NaOH, 20 μl of colipase solution (Sigma, 2 mg / ml), and 1 ml of the extract containing the test target were reacted at 25 ° C. for 60 minutes, and then the pH was again. The amount of NaOH used in the titration was measured by titrating with 10 mM NaOH to 8.8, and the inhibitory activity was calculated therefrom. The pancreatic lipase inhibitory activity of the ginseng processed product thus calculated is shown in Table 2 below (in Table 2 below, IC ₅₀ means a concentration capable of inhibiting lipase by 50%).

Ginseng extract or ginseng fermented product IC ₅₀ (mg / ml) Ginseng Extract 4.5 Ginseng Extract Fermentation Fermented with Bifidobacterium K-103 3.5 Ginseng Extract Fermentation Fermented with Bifidobacterium K-506 3.4 Ginseng Extract Fermentation Fermented with Bifidobacterium KK-1 3.5 Ginseng Extract Fermentation Fermented with Bifidobacterium KK-2 3.3 Ginseng Extract Fermentation Fermented with Bifidobacterium KK-11 3.4 Red Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 3.0 White Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 3.2 Red Ginseng Extract Fermentation Fermented with Lactobacillus K-1 3.5 Red Ginseng Extract Fermentation Fermented with Lactobacillus K-2 3.8 Red Ginseng Extract Fermentation Fermented with Lactobacillus K-3 3.9 Red Ginseng Extract Fermentation Fermented with Leuconostoc K-1 3.8 Red Ginseng Extract Fermentation Fermented with Leuconostoc K-2 3.9 Red Ginseng Extract Fermentation Fermented with Streptococcus K-1 3.5 Red Ginseng Extract Fermentation Fermented with Streptococcus K-2 3.7 Red Ginseng Extract Fermentation Fermented with Saccharomyces K-1 3.8 Red Ginseng Extract Fermentation Fermented with Gonoderma lucidum K-1 4.0 Red Ginseng Extract Fermentation Fermented with Monascus pilosus K-1 3.5 Red Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 and Lactobacillus K-1 2.5 Red Ginseng Extract Fermentation Fermented with Lactobacillus K-1 and Streptococcus K-1 2.8 Red Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 and Streptococcus K-1 2.9 Red Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 and Leuconostoc K-1 2.9 Xenical 0.8

Referring to Table 2, the ginseng processed product according to the present invention, it can be confirmed that has a significantly higher pancreatic lipase inhibitory activity than the control drug.

<Experiment 3: corn oil administration induced anti-hyperlipemia activity measurement in hyperlipidemia mice>

Six mice were treated with ginseng extract or fermented ginseng fermented with various lactic acid bacteria at 50 mg / kg / day for 5 days. The control group was orally administered saline instead of the ginseng extract or ginseng fermented product. Two hours later, corn oil was orally administered to each mouse at an amount of 1 g / kg, and the normal group was orally administered saline instead of corn oil. As a control drug, Xenical 10 mg / kg was orally administered. 2 hours after the time of corn oil administration, blood was collected from the heart, and the collected blood was centrifuged at 3000 rpm for 30 minutes to separate serum. The serum was used to measure the concentration of serum lipid component triglyceride (TG) and total cholesterol (TC). The results of measurement of antihyperlipidemic activity in corn oil administration-induced hyperlipidemic mice are shown in Table 3 below. Ginseng-treated product is not administered, followed by corn oil-treated mice).

group Dose (mg / kg / day) TG concentration (mg / dl) TC concentration (mg / dl) Normal - 33.4 ± 5.1 96.2 ± 6.53 Control - 105.6 ± 9.5 84.3 ± 3.7 Ginseng Extract 50 95.3 ± 4.2 85.4 ± 3.8 K-506 Fermented Ginseng Fermentation 50 81.5 ± 3.9 87.3 ± 6.2 H-1 Fermented Red Ginseng Fermentation 50 64.2 ± 5.9 80.0 ± 7.0 H-1 Fermented Ginseng Fermentation 50 71.3 ± 11.8 86.2 ± 6.6 Lactobacillus K-1 Fermented Red Ginseng Fermentation 50 78.8 ± 6.9 86.5 ± 8.8 Streptococcus K-1 Fermented Red Ginseng Fermentation 50 84.2 ± 9.9 83.3 ± 8.2 Leuconostoc K-1 Fermented Red Ginseng Fermentation 50 88.8 ± 11.5 84.0 ± 5.0 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Lactobacillus K-1 50 78.1 ± 7.9 83.3 ± 5.8 Red Ginseng Fermentation Fermented with Lactobacillus K-1 and Streptococcus K-1 50 84.2 ± 6.3 81.4 ± 6.9 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Streptococcus K-1 50 77.1 ± 6.1 87.9 ± 9.2 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Leuconostoc K-1 50 74.2 ± 15.9 87.2 ± 7.7 Xenical 10 61.3 ± 12.2 79.2 ± 6.5

From Table 3, it can be seen that the ginseng treated product according to the present invention, the anti-hyperlipidemic activity is significantly superior to the mice that do not.

<Experiment 4: Triton Determination of Antihyperlipidemic Activity in WR -1339 Induced Hyperlipidemic Mice >

Six mice were treated with ginseng extract or fermented ginseng fermented with various lactic acid bacteria at 50 mg / kg / day for 5 days. The control group was orally administered saline instead of the extract. Fasting was performed for 16 hours after the final administration, and then 250 mg / kg of triton WR-1339 was dissolved in sterile distilled water and injected into the tail vein, and the normal group was injected with saline instead of triton WR-1339. Then, after 18 hours, blood was collected from the examiner. As a control drug, lovastatin 10 mg / kg / day was orally administered.

When the ginseng processed product according to the present invention was administered to triton-induced hyperlipidemic model animals, the concentrations of triglyceride (TG) and total cholesterol (TC) in blood were measured, which are shown in Table 4 below (in Table 4, Normal). Represents a mouse to which the ginseng processed product according to the present invention is not administered and then saline administered, and Control represents a mouse to which the ginseng processed product is not administered and to which Triton WR-1339 was administered).

group Dose (mg / kg / day) TG concentration (mg / dl) TC concentration (mg / dl) Normal - 42.9 ± 10.7 83.3 ± 2.13 Control - 134.8 ± 15.2 299.8 ± 2.5 Ginseng Extract 50 120.8 ± 21.1 217.3 ± 22.5 K-506 Fermented Ginseng Fermentation 50 91.7 ± 18.4 207.9 ± 32.2 H-1 Fermented Red Ginseng Fermentation 50 70.8 ± 11.6 175.2 ± 31.2 H-1 Fermented Ginseng Fermentation 50 83.3 ± 21.2 201.3 ± 22.1 Lactobacillus K-1 Fermented Red Ginseng Fermentation 50 99.8 ± 12.4 202.2 ± 22.5 Streptococcus K-1 Fermented Red Ginseng Fermentation 50 86.3 ± 12.5 206.5 ± 22.5 Leuconostoc K-1 Fermented Red Ginseng Fermentation 50 79.9 ± 12.3 225.1 ± 35.2 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Lactobacillus K-1 50 68.5 ± 13.3 172.3 ± 31.8 Red Ginseng Fermentation Fermented with Lactobacillus K-1 and Streptococcus K-1 50 83.2 ± 12.5 203.5 ± 22.7 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Streptococcus K-1 50 69.8 ± 11.6 171.4 ± 29.5 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Leuconostoc K-1 50 76.3 ± 12.5 172.9 ± 32.7 Lovastatin 50 98.2 ± 12.6 132.2 ± 32.5

Referring to Table 4, it can be seen that the ginseng extract or ginseng fermented product according to the present invention significantly lowered the blood lipid concentration induced by Triton WR 1339.

< Experimental Example  5: α- Glycosidase  Inhibition Activity Measurement>

Five SD male rats (250-300 g) were anesthetized with ether and the small intestine isolated. The small intestine mucosa was scraped, suspended in 10 ml of phosphate buffer-physiological saline, sonicated three times for 15 seconds, and the supernatant obtained by centrifugation at 15000 rpm for 1 hour was used as α-glycosidase enzyme solution.

250 μl of substrate (2 mM p- nitrophenyl-α- D- glucopyranoside), 100 μl of test sample extract, and 200 μl of 0.1 M phosphate buffer (pH 7.0) were added to 50 μl of enzyme solution, followed by reaction at 37 ° C. for 30 minutes. The reaction was stopped by adding 500 μl of NaOH / NaHCO ₃ (pH 10). After centrifugation at 3000 rpm for 10 minutes, the supernatant was taken and measured for absorbance at 405 nm. The results are shown in Table 5 below.

Ginseng Extract or Ginseng Fermentation % Inhibition at 1 mg / ml Ginseng Extract 31 Ginseng Extract Fermentation Fermented with Bifidobacterium K-103 36 Ginseng Extract Fermentation Fermented with Bifidobacterium K-506 38 Ginseng Extract Fermentation Fermented with Bifidobacterium KK-1 41 Ginseng Extract Fermentation Fermented with Bifidobacterium KK-2 39 Ginseng Extract Fermentation Fermented with Bifidobacterium KK-11 38 Red Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 55 White Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 50 Red Ginseng Extract Fermentation Fermented with Lactobacillus K-1 45 Red Ginseng Extract Fermentation Fermented with Lactobacillus K-2 41 Red Ginseng Extract Fermentation Fermented with Lactobacillus K-3 42 Red Ginseng Extract Fermentation Fermented with Leuconostoc K-1 31 Red Ginseng Extract Fermentation Fermented with Leuconostoc K-2 32 Red Ginseng Extract Fermentation Fermented with Streptococcus K-1 38 Red Ginseng Extract Fermentation Fermented with Streptococcus K-2 41 Red Ginseng Extract Fermentation Fermented with Saccharomyces K-1 38 Red Ginseng Extract Fermentation Fermented with Gonoderma lucidum K-1 32 Red Ginseng Extract Fermentation Fermented with Monascus pilosus K-1 51 Red Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 and Lactobacillus K-1 61 Extracted Fermentation Water of Red Ginseng Fermented with Lactobacillus K-1 and Streptococcus K-1 ± Water 53 Red Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 and Streptococcus K-1 58 Red Ginseng Extract Fermentation Fermented with Bifidobacterium H-1 and Leuconostoc K-1 57 acarbose (control) 93

From Table 5, it can be seen that the ginseng extract or ginseng fermented product according to the present invention shows excellent α-glycosidase inhibitory activity.

< Experimental Example  6: Streptozotocin  Measurement of Glucose Lowering Effect in Induced Hyperglycemic Mice>

Intraperitoneal injection of 300 mg / kg of streptozotocin in 0.05M citrate buffer (pH 4.5) was carried out in some of the male ICR mice (weight 25 ± 5g), and blood glucose was measured 24 hours later. Mice falling within the range were selected. The selected mice were then fasted for 16 hours before being used for the experiment.

Maltose  Load experiment

Blood glucose was measured from the tail vein of each fasting normal and Streptozotocin-induced hyperglycemic mice for 16 hours before the experiment, followed by oral administration of 2 g / kg of maltose or starch and 50 mg / kg of sample simultaneously (30 minutes for maltose). Post-blood glucose was measured). Among these, the results obtained when maltose was loaded on normal animals are shown in Table 6 below, and the results when maltose was loaded on streptozotocin-treated diabetic model animals are shown in Table 7 below (in Tables 6 and 7, where Normal is normal). Animal group was treated with physiological saline instead of drug and maltose, and Control group was a group of diabetic model animals administered streptozotocin.

group Dose (mg / kg / day) Blood sugar level (mg / dl) Normal - 22.9 ± 6.5 Control - 121.8 ± 21.3 Ginseng Extract 50 91.8 ± 11.2 K-506 Fermented Ginseng Fermentation 50 87.2 ± 21.2 H-1 Fermented Red Ginseng Fermentation 50 78.2 ± 9.8 H-1 Fermented Ginseng Fermentation 50 88.2 ± 9.2 Lactobacillus K-1 Fermented Red Ginseng Fermentation 50 83.5 ± 9.2 Streptococcus K-1 Fermented Red Ginseng Fermentation 50 82.6 ± 12.2 Leuconostoc K-1 Fermented Red Ginseng Fermentation 50 87.7 ± 8.9 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Lactobacillus K-1 50 72.4 ± 14.4 Red Ginseng Fermentation Fermented with Lactobacillus K-1 and Streptococcus K-1 50 85.2 ± 7.5 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Streptococcus K-1 50 75.3 ± 15.5 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Leuconostoc K-1 50 74.5 ± 9.2 acarbose 20 62.3 ± 21.2

group Dose (mg / kg / day) Blood sugar level (mg / dl) Normal - 22.2 ± 10.3 Control - 221.8 ± 25.3 Ginseng Extract 50 170.2 ± 19.8 K-506 Fermented Ginseng Fermentation 50 161.7 ± 25.1 H-1 Fermented Red Ginseng Fermentation 50 147.8 ± 22.4 H-1 Fermented Ginseng Fermentation 50 150.8 ± 14.7 Lactobacillus K-1 Fermented Red Ginseng Fermentation 50 168.7 ± 15.3 Streptococcus K-1 Fermented Red Ginseng Fermentation 50 162.2 ± 16.5 Leuconostoc K-1 Fermented Red Ginseng Fermentation 50 182.5 ± 31.2 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Lactobacillus K-1 50 142.5 ± 23.2 Red Ginseng Fermentation Fermented with Lactobacillus K-1 and Streptococcus K-1 50 177.4 ± 28.4 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Streptococcus K-1 50 159.2 ± 17.3 Red Ginseng Fermentation Fermented with Bifidobacterium H-1 and Leuconostoc K-1 50 164.3 ± 22.8 acarbose 20 92.2 ± 32.4

Referring to Tables 6 and 7, it can be seen that the ginseng extract or ginseng fermented product according to the present invention significantly lowers the blood sugar.

Claims (13)

A functional food having at least one efficacy selected from the group consisting of obesity inhibition, antihyperlipidemia, antihypercholesterol, anti-blood triglycerides and glycemic control, including ginseng fermentation and food acceptable food supplement additives. The functional food according to claim 1, wherein the ginseng is selected from the group consisting of ginseng, red ginseng, white ginseng, rice ginseng, flower ginseng, ginseng leaf and ginseng powder. The functional food according to claim 1, wherein the ginseng is selected from the group consisting of ginseng and red ginseng, high temperature treated ginseng, acid treated ginseng and pressurized ginseng in dry powder form. The functional food according to claim 1, wherein the ginseng fermented product is obtained by fermenting ginseng with lactic acid bacteria. The method according to claim 4, wherein the lactic acid bacteria are selected from the group consisting of strains of the genus Lactobacillus, strains of Streptococcus, strains of Leukonostock, strains of Pediococcus, strains of Bifidobacterium, and combinations thereof. Functional food made with. The method according to claim 5, wherein the lactic acid bacteria are Bifidobacterium K-103, Bifidobacterium K-506, Bifidobacterium cholerium KK-1 (KCCM-10364), Bifidobacterium minimum KK-2 ( KCCM-10365), Bifidobacterium H-1 (KCCM-10493), Lactobacillus Ashdophilus K-1, Lactobacillus Ashdophilus K-2, Streptococcus Passium K-2, Leukonostock A functional food, characterized in that selected from the group consisting of mesenteroid K-1, leukonostock mesenteroid K-2, Saccharomyces cerevisia K-1, ganoderma lucidum K-1 and combinations thereof. A pharmaceutical composition having one or more efficacy selected from the group consisting of ginseng fermentation, obesity inhibition, antihyperlipidemic, antihypercholesterol, antiblood triglyceride, and glycemic control. The pharmaceutical composition according to claim 7, which has a formulation selected from the group consisting of powders, granules, tablets, capsules, solutions, and injections. 8. The pharmaceutical composition of claim 7, wherein the ginseng is selected from the group consisting of ginseng, red ginseng, white ginseng, rice ginseng, hwagi ginseng, ginseng leaves and ginseng powder. 8. The pharmaceutical composition according to claim 7, wherein the ginseng is selected from the group consisting of ginseng and red ginseng, high-temperature ginseng, acid-treated ginseng and pressurized ginseng in dry powder form. The pharmaceutical composition according to claim 7, wherein the ginseng fermentation product is obtained by fermenting ginseng with lactic acid bacteria. The method according to claim 11, wherein the lactic acid bacteria are selected from the group consisting of strains of the genus Lactobacillus, strains of Streptococcus, strains of Leukonostock, strains of Pediococcus, strains of Bifidobacterium, and combinations thereof. Pharmaceutical composition made with. The method of claim 12, wherein the lactic acid bacteria are Bifidobacterium K-103, Bifidobacterium K-506, Bifidobacterium cholrium KK-1 (KCCM-10364), Bifidobacterium minimum KK-2 ( KCCM-10365), Bifidobacterium H-1 (KCCM-10493), Lactobacillus Ashdophilus K-1, Lactobacillus Ashdophilus K-2, Streptococcus Passium K-2, Leukonostock A pharmaceutical composition, characterized in that it is selected from the group consisting of mecetheroid K-1, leukonostock mecetheroid K-2, Saccharomyces cerevisiae K-1, ganoderma lucidum K-1, and combinations thereof.